SOURCE: NeuroInvestment

March 07, 2007 09:00 ET

Schizophrenia Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA -- (MARKET WIRE) -- March 7, 2007 -- NI Research has released the March issue of NeuroInvestment, which reviews the status and prospects of treatments for schizophrenia, the most devastating of all psychiatric illnesses. Schizophrenia is estimated to affect up to three million Americans, and current antipsychotic drugs have only managed to shift the majority of those patients from hospital wards to the outskirts of society. In particular, contemporary drugs, which in fact are based on drug platforms of the 1950s and 1980s, fail miserably at the task of rekindling cognitive functioning and motivation for these patients.

This review briefly notes the numerous 'me-too' drugs currently available and under development, including drugs from Vanda Pharmaceuticals, Organon, and Solvay. The bulk of the review looks at the next generations of treatments for schizophrenia. This includes the most promising biochemical pathways for intervention: including glutamatergic, nicotinic, and 5HT-6 targets. Some of the programs worth watching are those from Cortex (AMEX: COR) partnered with Organon; Targacept (NASDAQ: TRGT); Acadia Pharmaceuticals (NASDAQ: ACAD); Intra-Cellular Therapies; Memory Pharmaceuticals, and a pioneering effort to achieve regeneration in schizophrenia, in development by Allon Therapeutics (TSX: NPC).

The March issue of NeuroInvestment also takes a closer look at such topics as Shire Pharmaceuticals' overpriced acquisition of New River Pharmaceuticals; the IPO filing by NeurogesX; the greatly improved prospects for Cortex's CX717 in ADHD; and includes a full review of privately held Xytis Pharmaceuticals.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1500, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three-month trial subscription is US$450.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and is now introducing an annual compendium of all neuro-oriented R&D programs organized by disorder, CNS 2007. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information